Advertisement

Topics

CytRx, Nantcell Strike Licensing Agreement for Aldoxorubicin

14:00 EDT 31 Jul 2017 | Drug Discovery Development

NantCell will be responsible for all future development, manufacturing and commercialization expenses.
Contributed Author: 
CytRx
Topics: 

Original Article: CytRx, Nantcell Strike Licensing Agreement for Aldoxorubicin

NEXT ARTICLE

More From BioPortfolio on "CytRx, Nantcell Strike Licensing Agreement for Aldoxorubicin"

Quick Search
Advertisement